{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:04:54Z","timestamp":1787015094024,"version":"build-2736575974"},"reference-count":56,"publisher":"Wiley","issue":"s1","license":[{"start":{"date-parts":[[2007,1,23]],"date-time":"2007-01-23T00:00:00Z","timestamp":1169510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Effective treatment options for hepatic encephalopathy are limited. Based on the principle that intestinal\u2010derived ammonia contributes to the pathogenesis of hepatic encephalopathy, current therapeutic approaches are directed at reducing bacterial production of ammonia and enhancing its elimination.<\/jats:p>\n                  <jats:p>\n                    Non\u2010absorbable disaccharides are first\u2010line therapy for hepatic encephalopathy, but published clinical studies evaluating their safety and efficacy are limited. Alternative therapies such as benzodiazepine receptor antagonists, branched\u2010chain amino acids, and\n                    <jats:sc>l<\/jats:sc>\n                    \u2010ornithine\u2010\n                    <jats:sc>l<\/jats:sc>\n                    \u2010aspartate also have limited clinical data supporting their use.\n                  <\/jats:p>\n                  <jats:p>Studies of antibiotics indicate that they are effective in the treatment of hepatic encephalopathy, but adverse effects and concerns about long\u2010term safety have limited the widespread use of most.<\/jats:p>\n                  <jats:p>Rifaximin is a minimally absorbed antibiotic that concentrates in the gastrointestinal tract and is excreted mostly unchanged in faeces. It has been studied extensively in the treatment of hepatic encephalopathy and appears to confer therapeutic benefits greater than those of placebo and non\u2010absorbable disaccharides and at least comparable with those of systemic antibiotics. Rifaximin was also well tolerated in patients with hepatic encephalopathy and is not associated with clinical drug interactions or clinically relevant bacterial antibiotic resistance.<\/jats:p>\n                  <jats:p>In conclusion, non\u2010absorbed antibiotics such as rifaximin offer a favourable benefit\u2013risk ratio in the treatment of hepatic encephalopathy and may help to improve patient outcomes.<\/jats:p>","DOI":"10.1111\/j.1746-6342.2006.03218.x","type":"journal-article","created":{"date-parts":[[2010,8,10]],"date-time":"2010-08-10T10:44:33Z","timestamp":1281437073000},"page":"23-31","source":"Crossref","is-referenced-by-count":50,"title":["Review article: the current pharmacological therapies for hepatic encephalopathy"],"prefix":"10.1111","volume":"25","author":[{"given":"N. M.","family":"BASS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,23]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2001.02.850"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03964.x"},{"key":"e_1_2_8_4_2","first-page":"646A","article-title":"Rifaximin treatment is beneficial for mild hepatic encephalopathy","volume":"40","author":"Bass NM","year":"2004","journal-title":"Hepatology"},{"key":"e_1_2_8_5_2","unstructured":"The Burden of Gastrointestinal Diseases. Bethesda Maryland:American Gastroenterological Association;2001;41\u20132."},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg110"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(99)80144-5"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708143370707"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0016-5085(77)80135-2","article-title":"Comparison of lactulose and neomycin in the treatment of chronic portal\u2010systemic encephalopathy","volume":"72","author":"Conn HO","year":"1977","journal-title":"Gastroenterology"},{"key":"e_1_2_8_10_2","first-page":"398","volume-title":"Am J Dig Dis","author":"Atterbury CE","year":"1978"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01295920"},{"key":"e_1_2_8_12_2","first-page":"890","article-title":"Treatment of chronic portal\u2010systemic encephalopathy with lactulose","volume":"1","author":"Bircher J","year":"1966","journal-title":"Lancet"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38048.506134.EE"},{"key":"e_1_2_8_14_2","first-page":"542","article-title":"Double\u2010blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy","volume":"39","author":"Strauss E","year":"1992","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_8_15_2","first-page":"1063","article-title":"Lactulose\u2010neomycin combination versus placebo in the treatment of acute hepatic encephalopathy. Results of a randomized controlled trial [in French]","volume":"18","author":"Blanc P","year":"1994","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.23.1.1"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1989-8_13"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(79)90649-1"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528708991867"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_2_8_21_2","volume-title":"Xifaxan [package insert]","year":"2005"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E407"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.05.019"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80681-2"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-200012020-00012"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999509111552"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00350-1"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999309111539"},{"key":"e_1_2_8_29_2","first-page":"7","article-title":"Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose","volume":"4","author":"Massa P","year":"1993","journal-title":"Eur J Clin Res"},{"key":"e_1_2_8_30_2","first-page":"57","article-title":"Rifaximin in the treatment of hepatic encephalopathy","volume":"4","author":"Giacomo F","year":"1993","journal-title":"Eur J Clin Res"},{"key":"e_1_2_8_31_2","first-page":"175","article-title":"Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics.\u00a0A double\u2010blind,\u00a0randomized trial","volume":"23","author":"Pedretti G","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"e_1_2_8_32_2","first-page":"403","article-title":"Rifaximine versus neomycin in the treatment of portosystemic encephalopathy","volume":"23","author":"Di\u00a0Piazza S","year":"1991","journal-title":"Ital J Gastroenterol"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007999709113333"},{"key":"e_1_2_8_34_2","first-page":"387","article-title":"A non\u2010absorbable rifamycin for treatment of hepatic encephalopathy","volume":"11","author":"Testa R","year":"1985","journal-title":"Drugs Exp Clin Res"},{"key":"e_1_2_8_35_2","first-page":"668","article-title":"Rifaximin in collateral treatment of portal\u2010systemic encephalopathy: a preliminary report","volume":"36","author":"De\u00a0Marco F","year":"1984","journal-title":"Curr Ther Res Clin Exp"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0011-393X(05)80433-3"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.curtheres.2004.10.002"},{"key":"e_1_2_8_38_2","first-page":"53","article-title":"Cyclic treatment of chronic hepatic encephalopathy with rifaximin: results of a double\u2010blind clinical study","volume":"49","author":"Loguercio C","year":"2003","journal-title":"Minerva Gastroenterol Dietol"},{"key":"e_1_2_8_39_2","first-page":"519A","article-title":"Safety and efficacy of rifaximin in the treatment of hepatic encephalopathy in liver cirrhosis","volume":"36","author":"Lata J","year":"2002","journal-title":"Hepatology"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2005.46.3.399"},{"key":"e_1_2_8_41_2","article-title":"Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy","author":"Leevy CB","journal-title":"Dig Dis Sci"},{"issue":"2","key":"e_1_2_8_42_2","first-page":"A\u2010806","article-title":"Is rifaximin cost\u2010effective in the management of hepatic encephalopathy?","volume":"130","author":"Spiegel BM","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840160123"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(90)90103-X"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)92119-6"},{"key":"e_1_2_8_46_2","first-page":"1266","article-title":"Severe recurrent hepatic encephalopathy that responded to oral branched chain amino acids","volume":"91","author":"Chalasani N","year":"1996","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840040218"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(89)91517-5"},{"key":"e_1_2_8_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/0148607196020002159"},{"key":"e_1_2_8_50_2","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/0016-5085(79)90399-8","article-title":"Treatment of chronic portal systemic encephalopathy with bromocriptine: a double\u2010blind controlled trial","volume":"76","author":"Uribe M","year":"1979","journal-title":"Gastroenterology"},{"key":"e_1_2_8_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280212"},{"key":"e_1_2_8_52_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510250609"},{"key":"e_1_2_8_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(98)80237-7"},{"key":"e_1_2_8_54_2","volume-title":"Levocarnitine [package insert]","year":"2004"},{"key":"e_1_2_8_55_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v11.i45.7197"},{"key":"e_1_2_8_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4684-5826-8_13"},{"key":"e_1_2_8_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00667-6"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1746-6342.2006.03218.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1746-6342.2006.03218.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T06:41:54Z","timestamp":1695710514000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1746-6342.2006.03218.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,23]]},"references-count":56,"journal-issue":{"issue":"s1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.1111\/j.1746-6342.2006.03218.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1746-6342.2006.03218.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,23]]}}}